Skip to main content

Table 2 Knowledge of filariasis in the community

From: Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance

Variables

Responses

Male (N = 334) % (95% CI)

Female (N = 357) % (95% CI)

Total (N = 691) % (95% CI)

What is filariasis?

Elephantiasis

61.6(65.4–74.8)

70.3(65.4–74.8)

67.8(64.3–71.3)

Lymphedema and elephantiasis

32.5(27.7–37.5)

29.1(24.6–34.0)

31.7(28.3–35.2)

Do not know

0.3(0.01–1.4)

0.56(0.1–1.70)

0.43(0.11–1.17)

Mode of transmission for filariasis?

Mosquito bite

90.4(86.9–93.2)

85.4(81.5–88.8)

87.8(85.2–90.1)

Hereditary/contagious

8.7(6.0–12.0)

13.1(9.9–16.5)

11(8.8–13.5)

Do not know

0.9(0.22–2.42)

1.4(0.5–3.07)

1.15(0.54–2.2)

Most common symptoms

Swelling of limbs

60.4(55.2–65.7)

34.0(29.1–39.0)

46.7(43.0–50.5)

Fever and swelling

38.6(33.5–44.0)

65.2(60.2–70.0)

52.4(48.6–56.1)

Do not know

0.9(0.22–2.42)

1.12(0.35–2.68)

1.0(0.44–2.0)

Treatment

Medicine

90.1(86.5–93.0)

85.0(80.5–88.0)

87.3(84.6–89.6)

Not curable

8.9(6.25–12.42)

13.4(10.2–17.3)

11.3(9.1–13.8)

Do not know

0.9(0.22–2.42)

1.96(0.9–3.8)

1.4(0.7–2.56)

Knowledge regarding the distribution of filarial tablets for prevention

Yes

95.5(92.9–97.4)

90.5(87.0–93.2)

92.9(90.8–94.6)

No

4.5(2.63–7.13)

9.5(6.8–12.9)

7.1(5.35–9.20)

Do you consider yourself to be at risk?

Yes

86.5(82.5–89.9)

80.9(76.6–84.7)

83.6(80.7–86.3)

No

12.3(9.0–16.13)

17.08(13.4–21.2)

14.7(12.2–17.5)

Do not know

1.2(0.4–2.9)

1.96(0.9–3.8)

1.6(0.83–2.75)